Modality
siRNA
MOA
ALKi
Target
EGFR
Pathway
Notch
Dravet
Development Pipeline
Preclinical
~Oct 2020
→ ~Jan 2022
Phase 1
Apr 2022
→ Dec 2026
Phase 1Current
NCT04426298
613 pts·Dravet
2022-04→2026-12·Active
613 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-018mo awayPh2 Data· Dravet
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2026-12-01 · 8mo away
Dravet
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04426298 | Phase 1/2 | Dravet | Active | 613 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |